Clinical Trials

Clinical Trial Detail

Search Clinical Trials

Return to search results.

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Complete title: A Randomized Placebo Controlled Double-Blind Study of Restasis® Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation

Research Study Number       2321.00
    
Principal Investigator       Mary Flowers, MD
    
Phase       III

Look up trial at NIH

Research Study Description

RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.

PURPOSE: This randomized phase I trial is studying how well cyclosporine eye drops work in preventing graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

- Age greater than or equal to 18 years at time of enrollment

- Day 80-120 after first allogeneic stem cell transplant for hematologic malignancies or -marrow failure disorder at time of study enrollment

- Signed informed consent

- Willing to adhere to protocol requirements

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- history of non-compliance

- diagnosis of ocular GVHD at time of study enrollment

- documented dry eye prior to onset of stem cell transplant

- significant non- GVHD ocular problems that precludes participation in study

- life expectancy of lesser than 6 months at time of enrollment (viz. grade 4 acute GVHD, florid progression or relapse of underlying disease)

- history of documented ocular infections prior to stem cell transplant or during transplant (i.e. history of herpetic keratitis)

- females who are pregnant or breastfeeding

Other exclusion criteria may apply.



Research Study Number       2321.00
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
    

Keywords
Leukemia; Lymphoma; Chronic Graft Versus Host Disease (cGVHD)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.